Experts unpack advanced cutaneous squamous cell carcinoma risks, comorbidities, and PD-1/PD-L1 immunotherapy strategies for unresectable disease.
Megan Schollenberger, MSN, BSN, CRNP
Advertisement
Articles by Megan Schollenberger, MSN, BSN, CRNP
Experts unpack unresectable cutaneous squamous cell carcinoma, weighing PD-1/PD-L1 immunotherapy benefits and risks in older, comorbid patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines
2
Generic Enzalutamide Receives Tentative FDA Approval in Prostate Cancer
3
40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study
4
Cellular Therapy and Antibody-Drug Conjugates Shape Day 1 of ASCO Breakthrough 2026
5